Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study.

Yuri Takamatsu, Yoshiya Horimoto, Yasuo Miyoshi, Junichiro Watanabe, Goro Kutomi

Abstract readMulticenter Study

In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yuri TakamatsuDepartment of Breast Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan.ORCID http://orcid.org/0009-0001-4790-7529

Yoshiya HorimotoDepartment of Breast Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan.ORCID http://orcid.org/0000-0001-8935-0768

Yasuo MiyoshiDepartment of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.ORCID http://orcid.org/0000-0001-8535-4008

Junichiro WatanabeDepartment of Breast Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan. j.watanabe.vq@juntendo.ac.jp.ORCID http://orcid.org/0000-0001-9226-895X

Goro KutomiDepartment of Breast Oncology, Faculty of Medicine, Juntendo University, Tokyo, Japan.ORCID http://orcid.org/0000-0003-4557-5126

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the EMBRACE study, eribulin (ERI) monotherapy improved the overall survival (OS) of patients with HER2-negative advanced breast cancer (HER2-negative ABC). A post hoc analysis identified the baseline absolute lymphocyte count (ALC) as a predictive marker in the ERI arm; nevertheless, factors affecting post-ERI had not been well explored. PATIENTS AND

methodsWe retrospectively analyzed clinical data of 370 patients receiving ERI for HER2-negative ABC between July 2011 and June 2024 across 3 institutions. Clinical data, including ALC, were extracted. Statistical analyses included the log-rank test and Cox hazard model. The OS was defined as survival from ERI initiation (OS1) and from ERI termination (OS2).

resultsIdentical to the previous report, the OS1 was significantly improved in patients with ALC ≥ 1000/μL at ERI initiation and with ER-positive. Regarding the OS2, we identified independent factors which significantly improve the OS2 as follows: ALC ≥ 1000/μL at the termination of ERI, ≥ 120 days time-to-treatment-discontinuation of ERI, and first-line use of ERI. Furthermore, ALC was maintained during ERI therapy, whereas it significantly decreased in other regimens (P < 0.001).

conclusionAn ALC ≥ 1000/μL at ERI completion was associated with an improved post-ERI OS (OS2). It is suggested that not only the factors at the initiation of ERI, but also the immunological status at the end of ERI, may have prognostic value after ERI.

Indexed as

Breast NeoplasmsFuransKetonesAdultAgedBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansLymphocyte CountMiddle AgedPolyether PolyketidesPrognosisRetrospective StudiesBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinaseseribulinFuransKetonesPolyether PolyketidesAbsolute lymphocyte countEribulinHER2-negative breast cancerPost-progression survivalPredictive marker

Identifiers

PMID41619158

DOI10.1007/s10147-026-02977-5

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.